1 / 1

Targeted Biologic Agents in Rheumatic Diseases: Antibody and Receptor Therapies

This figure illustrates the currently approved and in-trial antibody-based and receptor-based biologic agents (highlighted in red) that target primary immune cells (B cells, T cells, macrophages, endothelial cells, osteoclasts, and fibroblasts) alongside circulating mediators such as TNF, IL-15, VEGF, RANKL, BLyS, and CD80/CD86. These agents represent significant advancements in the treatment of rheumatic diseases, as explored by Rothe et al. (2008) in their review of therapeutic innovations utilizing recombinant proteins.

baka
Télécharger la présentation

Targeted Biologic Agents in Rheumatic Diseases: Antibody and Receptor Therapies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Figure 1 Approved or in-trial antibody-based and receptor-based biologic agents (in red) targeting either primary cells (B cells, T cells, macrophages, endothelial cells, osteoclasts and fibroblasts) and/or the circulating mediators (TNF, IL-15, VEGF, RANKL, BLyS, CD80/CD86) involved in rheumatic diseases Rothe A et al. (2008) Therapeutic advances in rheumatology with the use of recombinant proteins Nat Clin Pract Rheumatol doi:10.1038/ncprheum0909

More Related